1. Home
  2. MDXH vs ICCM Comparison

MDXH vs ICCM Comparison

Compare MDXH & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.76

Market Cap

21.1M

Sector

N/A

ML Signal

HOLD

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$2.71

Market Cap

20.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDXH
ICCM
Founded
2003
2006
Country
Belgium
Israel
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
21.1M
20.4M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
MDXH
ICCM
Price
$0.76
$2.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$7.67
$2.50
AVG Volume (30 Days)
15.5M
73.5K
Earning Date
05-14-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.78
$139.51
Revenue Next Year
$18.31
$75.66
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$0.13
52 Week High
$5.33
$9.54

Technical Indicators

Market Signals
Indicator
MDXH
ICCM
Relative Strength Index (RSI) 69.42 41.86
Support Level $0.68 $0.45
Resistance Level $2.23 $3.59
Average True Range (ATR) 0.10 0.34
MACD 0.05 -0.02
Stochastic Oscillator 48.84 20.72

Price Performance

Historical Comparison
MDXH
ICCM

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: